AbCellera

investment firm

About

AbCellera is an antibody discovery and development engine, finding optimal clinical candidates for our partners.

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$817.87K
Industries
Artificial Intelligence,Biotechnology,Machine Learning,Medical,Therapeutics
Founded date
Jan 1, 2012
Operating Status
Active
Stock Symbol
nasdaq:ABCL
Legal Name
AbCellera Biologics Inc.

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner.

With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success. 

We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$853.21M
AbCellera has raised a total of $853.21M in funding over 2 rounds. Their latest funding was raised on Dec 10, 2020 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 10, 2020 IPO $482M Detail
May 27, 2020 Series B $105M 8 DCVC
OrbiMed
Detail
May 3, 2020 Grant $175.60M 1 Government of Canada Detail
Mar 23, 2020 Series A $75M 5 DCVC Bio
OrbiMed
Detail
Mar 14, 2019 Grant $4.80M 1 Detail

Investments

Number of Investments
Number of Lead Investments
2
0
AbCellera has made 2 investments. Their most recent investment was on Sep 30, 2020, when Invetx raised $10.25M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 30, 2020 Invetx
Series A $10.25M Biopharma
Feb 24, 2020 Invetx
Series A $15M Biopharma

Investors

Number of Lead Investors
Number of Investors
6
12
AbCellera is funded by 12 investors. DCVC and OrbiMed are the most recent investors.
Investor Name Lead Investor Funding Round
DCVC Yes Series B
OrbiMed Yes Series B
Government of Canada Yes Grant
DCVC Bio Yes Series A
Eli Lilly Series B
Founders Fund Series B
Peter Thiel Series B
Presight Capital Series B
University of Minnesota Series B
Viking Global Investors Series B

Employee Profiles

Number of Employee Profiles
10
AbCellera has 10 current employee profiles, including Board member John Hamer
Board member
Executive
Executive
Executive
Employee

Acquisition

AbCellera has acquired 4 organizations. Their most recent acquisition was Lineage Biosciences on Aug 1, 2018. They acquired Lineage Biosciences for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition Detail
Biotechnology acquisition Detail
Nov 18, 2020 Trianni
Biotechnology acquisition $ 90M Detail
Sep 13, 2021 Tetragenetics
Biopharma acquisition Detail